RECRUITING

The C-MERIT Screening Cohort: Contrast-enhanced Mammography for Breast Cancer Screening and Risk Assessment in Women With Dense Breasts

Talk to us

Conditions

Breast Cancer

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

To learn whether a new imaging technology, Contrast-Enhanced Mammography (CEM), compared to standard mammography, can better detect breast cancers in women with dense breasts

Official Title

The C-MERIT Screening Cohort: Contrast-enhanced Mammography for Breast Cancer Screening and Risk Assessment in Women With Dense Breasts

Quick Facts

Study Start:2022-12-05
Study Completion:2027-12-31
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05667532

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:30 Years to 75 Years
Sexes Eligible for Study:FEMALE
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. 1. Female patients 30-75 years of age with dense breasts (ACR BI-RADS categories C and D) who undergo routine yearly mammography at participating MDACC sites
  2. 2. Willingness to co-enroll or currently enrolled in PA17-0584
  3. 3. Willingness to participate in the study and ability to provide informed consent
  1. 1. Self-reported new breast symptoms since last mammogram including nipple discharge, palpable mass, skin dimpling, or focal pain.
  2. 2. Current or recent (within the prior 6 months) history of pregnancy or breast feeding
  3. 3. Personal history of breast cancer (DCIS or invasive breast cancer)
  4. 4. Treatment of any other type of cancer within the past 5 years excluding in-situ cervical and non-melanoma skin cancer
  5. 5. Breast biopsy within 6 months
  6. 6. Breast surgery within 12 months
  7. 7. Breast MRI, MBI, or CEM performed within 24 months
  8. 8. Known allergy to iodine-containing contrast agents
  9. 9. History of anaphylactic reaction to any substance that required hospitalization or IV placement in a patient with no known prior uneventful exposure to iodine-based IV contrast
  10. 10. Renal insufficiency (as defined by UTMDACC policy 3.30- attachment 1 (appendix D)

Contacts and Locations

Study Contact

Olena Weaver, MD
CONTACT
(713) 745-4555
ooweaver@mdanderson.org

Principal Investigator

Olena Weaver, MD
PRINCIPAL_INVESTIGATOR
M.D. Anderson Cancer Center

Study Locations (Sites)

M D Anderson Cancer Center
Houston, Texas, 77030
United States

Collaborators and Investigators

Sponsor: M.D. Anderson Cancer Center

  • Olena Weaver, MD, PRINCIPAL_INVESTIGATOR, M.D. Anderson Cancer Center

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2022-12-05
Study Completion Date2027-12-31

Study Record Updates

Study Start Date2022-12-05
Study Completion Date2027-12-31

Terms related to this study

Additional Relevant MeSH Terms

  • Breast Cancer